Syndax Pharmaceuticals, Inc. Effective Income Tax Rate Reconciliation, Tax Credit, Percent
Syndax Pharmaceuticals, Inc. (SNDX) reported Effective Income Tax Rate Reconciliation, Tax Credit, Percent of -1.10% for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits · last filed 2026-02-26
- Syndax Pharmaceuticals, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2024 was -1.10%.
- Syndax Pharmaceuticals, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2023 was -1.50%.
- Syndax Pharmaceuticals, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2022 was -1.00%, a 120.00% decline from fiscal 2021.
- Syndax Pharmaceuticals, Inc. effective income tax rate reconciliation, tax credit, percent for fiscal 2021 was 5.00%.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month | Effective Income Tax Rate Reconciliation, Tax Credit, Percent 12 month as first filed |
|---|---|---|
| 2024-12-31 | -1.10% 10-K · filed 2026-02-26 | |
| 2023-12-31 | -1.50% 10-K · filed 2026-02-26 | |
| 2022-12-31 | -1.00% 10-K · filed 2025-03-03 | |
| 2021-12-31 | 5.00% 10-K · filed 2024-02-27 | |
| 2020-12-31 | -0.90% 10-K · filed 2023-02-28 | 0.90% 10-K · filed 2021-03-12 |
| 2019-12-31 | -0.90% 10-K · filed 2022-03-01 | 0.90% 10-K · filed 2021-03-12 |
| 2018-12-31 | 0.80% 10-K · filed 2021-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |